MiMedx Group (NASDAQ:MDXG) Shares Gap Down on Disappointing Earnings

MiMedx Group, Inc (NASDAQ:MDXG) shares gapped down prior to trading on Thursday following a dissappointing earnings announcement. The stock had previously closed at $4.23, but opened at $3.90. MiMedx Group shares last traded at $4.0650, with a volume of 977,332 shares.

The company reported ($0.05) EPS for the quarter, missing the consensus estimate of ($0.03) by ($0.02). The business had revenue of $64.36 million during the quarter, compared to analyst estimates of $63.46 million. MiMedx Group had a net margin of 7.88% and a return on equity of 21.03%.

MiMedx Group News Summary

Here are the key news stories impacting MiMedx Group this week:

• Positive Sentiment: MiMedx reported second-quarter revenue of approximately $64.4 million, exceeding analysts’ $63.5 million estimate. Management also reiterated its standalone fiscal 2026 revenue outlook of $260 million to $290 million. MIMEDX Announces Second Quarter 2026 Operating and Financial Results
• Positive Sentiment: The company agreed to acquire Sanara MedTech in a cash-and-stock transaction valued at $35 per Sanara share, with an enterprise value of approximately $350 million. MiMedx expects the combination to nearly double surgical revenue, improve gross and adjusted EBITDA margins, and generate more than $20 million in annual run-rate cost synergies. MIMEDX to Acquire Sanara MedTech
• Positive Sentiment: Following the planned Sanara transaction, management outlined 2027 revenue of well above $400 million and an adjusted EBITDA margin exceeding 20%, supporting the strategic-growth case for the deal. MiMedx outlines 2027 revenue and EBITDA targets

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on MDXG. Wall Street Zen cut shares of MiMedx Group from a “buy” rating to a “hold” rating in a research note on Saturday, May 2nd. Craig Hallum decreased their target price on shares of MiMedx Group from $10.00 to $7.00 and set a “buy” rating for the company in a research report on Friday, April 17th. Citizens Jmp lowered their target price on shares of MiMedx Group from $7.00 to $6.00 and set a “market outperform” rating on the stock in a research note on Thursday, April 30th. Finally, Weiss Ratings cut shares of MiMedx Group from a “sell (d+)” rating to a “sell (d)” rating in a report on Monday, May 18th. Six equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, MiMedx Group presently has an average rating of “Moderate Buy” and an average target price of $8.50.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Allspring Global Investments Holdings LLC grew its stake in shares of MiMedx Group by 433.2% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 289,199 shares of the company’s stock worth $1,958,000 after purchasing an additional 234,958 shares during the last quarter. Hillsdale Investment Management Inc. acquired a new stake in MiMedx Group during the fourth quarter valued at approximately $7,134,000. Vanguard Group Inc. lifted its stake in MiMedx Group by 5.6% during the fourth quarter. Vanguard Group Inc. now owns 7,184,262 shares of the company’s stock valued at $48,637,000 after purchasing an additional 382,623 shares during the last quarter. OP Asset Management Ltd bought a new stake in MiMedx Group during the first quarter worth approximately $2,406,000. Finally, Paradigm Capital Management Inc. NY boosted its holdings in MiMedx Group by 39.1% during the first quarter. Paradigm Capital Management Inc. NY now owns 3,410,300 shares of the company’s stock worth $13,471,000 after buying an additional 959,100 shares in the last quarter. 79.15% of the stock is owned by institutional investors and hedge funds.

MiMedx Group Stock Performance

The company has a quick ratio of 4.81, a current ratio of 5.39 and a debt-to-equity ratio of 0.07. The stock has a market cap of $594.01 million, a price-to-earnings ratio of 20.06 and a beta of 1.45. The company’s 50-day simple moving average is $3.90 and its 200-day simple moving average is $4.25.

MiMedx Group Company Profile

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.